SGA
BMRN icon

Sustainable Growth Advisers’s BioMarin Pharmaceuticals BMRN Stock Holding History

Sustainable Growth Advisers’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-15,355
Closed -$1.11M – 47
2014
Q3 		$1.11M Buy
+15,355
New +$1.01M 0.02% 43

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Sustainable Growth Advisers's BMRN Position: Q4 2014 in Review

Sustainable Growth Advisers sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2014, closing a stake of 15,355 shares — an estimated $1.11M sold.

Sustainable Growth Advisers first reported a position in BMRN in Q3 2014 and held it in 1 quarter. The position peaked at $1.11M in Q3 2014. 341 funds tracked by Wall St. Rank hold BMRN as of Q4 2014.

  • Sustainable Growth Advisers reported no remaining BioMarin Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • Sustainable Growth Advisers sold 15,355 BioMarin Pharmaceuticals shares in Q4 2014, an estimated $1.11M.
  • Sustainable Growth Advisers first reported a position in BioMarin Pharmaceuticals in Q3 2014 and held it in 1 quarter.
  • Sustainable Growth Advisers's BioMarin Pharmaceuticals position peaked at $1.11M in Q3 2014.
  • 341 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2014.

Based on Sustainable Growth Advisers's 13F filing for Q4 2014, filed 6 Feb 2015.